The trial conducted at the WRAIR Clinical Trial Center in Silver Spring, Md., is assessing the
impact of pre-existing
flavivirus immunity in volunteers who had been vaccinated against yellow fever or Japanese encephalitis — both viral cousins to Zika — prior to receiving ZPIV.
It notes some of the critical scientific questions regarding Zika that deserve further exploration, including: whether certain viral mutations occurred to facilitate its geographical spread; if different species of Aedes mosquitoes are capable of transmitting Zika and what that may mean for future transmission; what is apparently unique to Zika compared to other more well - known
flaviviruses, such as dengue, that can explain why it can cause congenital infections, neurological conditions and encephalitis, transmit sexually and persist for long periods of time in multiple parts of the human body; and whether preexisting immunity to other related
flaviviruses may
impact Zika exposure and infection.